Restoration Recovery is an outpatient addiction clinic in Southeast Tennessee and Northwest Georgia. The rapid regulatory shift around 7-hydroxymitragynine is a live topic for patients we see every week, because supply disruption — whether from a federal schedule or a state-level ban — affects whether they can safely taper or need to transition to treatment. This page is factual reporting on the federal scheduling status of 7-OH as of April 24, 2026; it is not legal advice. For state-level status, see our companion kratom laws by state tracker.

Where 7-OH federal status stands today

As of April 24, 2026, 7-hydroxymitragynine is not a controlled substance under the federal Controlled Substances Act. It is not on Schedule I, II, III, IV, or V. It is federally legal to manufacture, sell, and possess, subject to general FDA authority over product marketing and labeling claims. The FDA does not approve 7-OH for any medical use, and products marketed with unapproved drug claims have drawn FDA warning letters. But possession itself is not a federal criminal offense.

The federal picture has been in motion since mid-2025 and is expected to move further during 2026. Three federal actions shape the current landscape:

January 22, 2025 — DEA “Drugs of Concern” designation

The DEA formally designated both kratom (mitragynine) and 7-hydroxymitragynine as Drugs of Concern. This administrative label signals that an agency views a substance as potentially abusable without formally scheduling it. The designation does not create any criminal prohibition or enforcement authority on its own; it is a predicate that can support future scheduling action. For 7-OH specifically, the Drugs of Concern designation was a significant step because it signaled the DEA’s intent to pursue a path toward formal scheduling if the FDA’s safety review supported that direction.

July 15, 2025 — FDA warning letters

The FDA issued warning letters to seven companies marketing 7-OH products. The letters cited unapproved new drug claims (marketing products as pain, anxiety, or opioid-alternative treatments without FDA approval) and misbranding under the Federal Food, Drug, and Cosmetic Act. The warning letters required corrective action on product labeling and marketing but did not by themselves prohibit sale. The actions signaled that the FDA intended to move further on 7-OH specifically, and they pre-positioned the agency for the Schedule I recommendation that followed two weeks later.

July 29, 2025 — FDA Schedule I recommendation to DEA

On July 29, 2025, the FDA formally recommended that the DEA classify concentrated 7-hydroxymitragynine products as Schedule I controlled substances under the Controlled Substances Act. The scope of the recommendation is important and often misreported:

  • The recommendation targeted concentrated 7-OH products specifically — tablets, gummies, drink mixes, and shots with elevated 7-OH concentrations.
  • Natural whole-leaf kratom was not the focus. Mitragynine in natural kratom leaf is present in much lower relative concentrations than in isolated 7-OH products, and the FDA recommendation did not propose to schedule natural kratom leaf.
  • The FDA recommendation was based on the agency’s analysis of 7-OH’s opioid pharmacology, dependence potential, and the absence of an FDA-approved medical indication.

What the DEA is doing now

The DEA received the FDA’s Schedule I recommendation in late July 2025 and is reviewing it through the agency’s standard rulemaking process. As of April 24, 2026, the DEA has not:

  • Published a proposed rule in the Federal Register to schedule 7-OH
  • Opened a public-comment period
  • Issued an emergency or temporary scheduling order
  • Made any final scheduling determination

The DEA could use emergency-scheduling authority to place 7-OH on Schedule I without going through full notice-and-comment rulemaking, but the agency has not signaled that it intends to do so. The standard rulemaking process is the more likely path, and it takes time. For context, the 2016 attempt to temporarily schedule kratom itself was withdrawn after significant public opposition during a comment period; the DEA is likely cautious about repeating that process without broader consensus on 7-OH specifically.

How federal scheduling works — the rulemaking timeline

When an agency like the FDA recommends a scheduling action, the DEA becomes the lead on the formal process. That process typically proceeds through these stages:

  1. DEA scientific and medical review. The DEA reviews the FDA’s supporting evidence, including abuse potential, dependence liability, current medical use, and international treaty obligations. This can take months.
  2. Notice of proposed rulemaking. If the DEA decides to pursue scheduling, it publishes a proposed rule in the Federal Register. The proposed rule states the schedule placement, effective date, and legal basis.
  3. Public comment period. The agency opens a comment period, typically 30 to 60 days though sometimes longer for substances with significant public interest. Industry groups, medical associations, consumer advocacy organizations, and individual citizens can submit comments.
  4. Review of comments. The DEA reviews public comments and responds to substantive concerns in its final rule.
  5. Final rule. The DEA publishes a final rule in the Federal Register, which establishes the scheduling placement and effective date.
  6. Effective date. After the effective date, possession, sale, and manufacture of the scheduled substance are federal criminal offenses under the Controlled Substances Act.

Timing across all stages is uncertain. For a substance with the consumer and commercial profile of 7-OH, 18 to 36 months from recommendation to final rule is a reasonable estimate, though the DEA can move faster with emergency-scheduling authority or slower if commentary identifies procedural concerns.

State-level 7-OH status

State law moves on a separate track from federal scheduling. In states that ban kratom under state controlled-substance statutes, 7-OH is almost always banned alongside kratom because state statutes typically cover mitragynine and 7-hydroxymitragynine together as “kratom alkaloids” or equivalent terminology. As of April 2026, 7-OH is banned at the state level in seven states: Alabama, Arkansas, Indiana, Louisiana, Vermont, Wisconsin, and Connecticut. Tennessee would add 7-OH to its banned-substance list if Gov. Bill Lee signs HB1649/SB1656, which is currently on his desk with an effective date of July 1, 2026 if signed.

In Kratom Consumer Protection Act states, 7-OH is typically regulated rather than banned. Most KCPA frameworks cap 7-OH at 2 percent of total alkaloid content in any kratom product sold in the state and prohibit synthetic 7-OH additives. Concentrated 7-OH products — isolate tablets, gummies, drink shots — usually exceed the concentration cap and are therefore effectively unavailable for legal retail sale in KCPA states, even though natural kratom leaf products remain legal.

For the full state-by-state picture, see our kratom laws by state 2026 tracker.

What DEA scheduling would actually mean

If and when the DEA schedules 7-OH as Schedule I, the practical effects are substantial:

  • Federal criminal offense. Manufacturing, distributing, or possessing 7-OH becomes a federal controlled-substance offense, regardless of state law.
  • Retail sale ends. Smoke shops, gas stations, and online retailers across the country have to cease 7-OH product sales on the effective date.
  • Natural kratom leaf status unchanged — unless separately addressed. If the scheduling action targets only concentrated 7-OH, natural whole-leaf kratom remains federally unscheduled. Most observers expect a future scheduling action on mitragynine itself would require a separate FDA recommendation and DEA rule.
  • State ban-state status becomes less distinctive. Ban states were already prohibiting 7-OH; federal scheduling would pull the KCPA states into the same prohibition posture for concentrated 7-OH products.

What this means for treatment

Federal or state scheduling does not change treatment for 7-OH or kratom dependence. Buprenorphine-based medication-assisted treatment (Suboxone, Sublocade, Brixadi) has an FDA-approved indication for opioid use disorder, and because 7-OH and mitragynine act on the same mu-opioid receptors as prescription opioids, buprenorphine is clinically effective for 7-OH dependence. These medications remain legal, insurance-covered, and protected by 42 CFR Part 2 confidentiality rules regardless of how federal or state 7-OH status evolves.

If you are physically dependent on 7-OH products, do not stop abruptly to get ahead of a potential ban. Abrupt cessation from concentrated 7-OH produces opioid-style withdrawal that is relapse-prone and clinically difficult to manage without medication support. A supervised transition with buprenorphine is safer and more effective. Our providers treat 7-OH dependence specifically; see our kratom and 7-OH addiction treatment page and our explainer on why concentrated 7-OH products behave differently from natural kratom leaf.

Common questions about 7-OH scheduling

Is 7-OH banned in the U.S. as of April 2026?

No. 7-hydroxymitragynine is not federally scheduled or banned as of April 2026. The FDA formally recommended Schedule I classification to the DEA on July 29, 2025, but the DEA has not published a proposed rule, and federal scheduling requires a rulemaking process with a public-comment period. Several states ban 7-OH along with kratom under state-level controlled-substance statutes, but there is no federal prohibition on 7-OH at this time.

What did the FDA recommend in July 2025?

On July 29, 2025, the FDA formally recommended to the DEA that concentrated 7-hydroxymitragynine products be classified as Schedule I controlled substances under the Controlled Substances Act. The recommendation was narrow in scope: it targeted concentrated 7-OH products such as tablets, gummies, drink mixes, and shots with elevated 7-OH concentrations. Natural whole-leaf kratom was not the focus of the FDA recommendation. Two weeks earlier, on July 15, 2025, the FDA had issued warning letters to seven companies marketing 7-OH products citing unapproved new drug claims and misbranding.

How long does federal scheduling take?

Federal scheduling through the DEA’s standard rulemaking process typically takes months to years. The DEA reviews the FDA recommendation and supporting scientific evidence, publishes a proposed rule in the Federal Register, opens a public-comment period (typically 30 to 60 days, sometimes longer), reviews comments, and then publishes a final rule. Final scheduling actions on substances like 7-OH can move faster if the DEA uses emergency-scheduling authority, but the standard process is closer to 18 to 36 months from recommendation to final rule.

Does 7-OH scheduling change treatment options for dependence?

No. Treatment for 7-OH or kratom dependence uses buprenorphine-based medications (Suboxone, Sublocade, Brixadi) that have FDA-approved indications for opioid use disorder. Because 7-OH and mitragynine act on the same mu-opioid receptors as prescription opioids, buprenorphine is clinically effective for 7-OH dependence. These medications remain legal, insurance-covered, and protected by 42 CFR Part 2 confidentiality rules regardless of how federal or state 7-OH scheduling evolves.

Can I still buy 7-OH products today?

Whether 7-OH products are legal to purchase depends on your state. In states that ban kratom (Alabama, Arkansas, Indiana, Louisiana, Vermont, Wisconsin, and Connecticut as of April 2026), 7-OH is banned along with kratom because state statutes typically cover mitragynine and its derivatives. In states with Kratom Consumer Protection Act frameworks, 7-OH is regulated rather than banned, with most KCPA states capping 7-OH concentration at 2 percent of total alkaloids and prohibiting synthetic additives. Federally, 7-OH is not scheduled, so sale and possession are federally legal even in states without specific restrictions.

Where to check current status

Federal scheduling actions are published in the Federal Register. The DEA Diversion Control Division and the FDA press-release pages are the authoritative federal sources. For state-level 7-OH status, LegiScan, BillTrack50, and state legislature websites publish bill tracking and statute text. The American Kratom Association also maintains a state status tracker on the advocacy side. We update this article as federal scheduling status changes meaningfully.

This article is published for patient information only. It is not legal advice. If you have a specific legal question about 7-OH in your state or a cross-border scenario, consult an attorney licensed in the relevant jurisdiction.

If you are dependent on 7-OH or kratom

The clinical picture for 7-OH and kratom dependence does not depend on federal scheduling. Buprenorphine-based MAT works, same-week appointments are available at all four of our clinics across Southeast Tennessee and Northwest Georgia, and most insurance plans cover treatment. Call 423-498-2000 or book a callback when you are ready. Do not wait for a federal or state action to stop cold turkey — a supervised transition with medication is safer.

Related reading